Oct 02 2026 09:55 PM EST

United Therapeutics Gains on Patent Victory, FDA IPF NDA Acceptance and Accelerated Buyback

United Therapeutics (NASDAQ: UTHR) rallied more than 13 % over the past five days, driven by a court‑ordered patent win, FDA acceptance of a new IPF indication for its nebulized Tyvaso product, and the completion of a $477.6 million accelerated share‑repurchase (ASR). The combination of legal protection, a potential new revenue stream and a substantial reduction in float has prompted analysts to raise price targets while highlighting lingering revenue‑growth concerns.

Court ruling secures Tyvaso franchise

A Delaware federal judge found that Liquidia Corp. infringed United Therapeutics’ patents covering inhaled treprostinil (claims 1 and 14 of U.S. Patent No. 11,826,327). The decision affirms market exclusivity for the Tyvaso platform and eliminates a near‑term competitive threat. Investors interpreted the ruling as a catalyst that protects the high‑margin DPI franchise, which posted a $326.6 million revenue increase (+9 % YoY) in Q2 2026.

FDA accepts supplemental NDA for nebulized Tyvaso in IPF

The agency announced acceptance of a supplemental New Drug Application that seeks approval of nebulized Tyvaso for idiopathic pulmonary fibrosis (IPF). The sNDA is based on positive Phase 3 TETON‑1/2 data and carries orphan‑drug designations in the United States and the European Union. The PDUFA target is late April 2027, and a successful approval would add a first‑in‑class inhaled antifibrotic therapy to United’s portfolio, potentially offsetting the 18 % YoY decline in nebulized Tyvaso sales ($126.0 million in Q2 2026).

Accelerated share‑repurchase tightens float

United executed a $477.6 million ASR with Citibank in September 2026, completing the $2 billion buy‑back programme authorized to March 9 2027. The transaction retired roughly 75 % of the remaining shares, reducing outstanding shares to about 42.9 million. The share‑count contraction, combined with ongoing buy‑backs, has lifted diluted EPS to $7.27 in Q2 2026 (≈6 % above consensus) while revenue slipped 2 % YoY to $783.3 million.

Financial snapshot

United reported FY 2025 revenue of $3.18 billion, an 11 % YoY increase, and net income of $1.33 billion. Gross margin remains robust at roughly 86 % (TTM 2026), while operating margin fell to 42.2 % in Q2 2026. Cash and equivalents stood at $3.47 billion as of March 31 2026 and $1.80 billion at June 30 2026, providing ample liquidity for continued buy‑backs and pipeline investments.

Analyst reaction and market positioning

BTIG upgraded United to “Buy” with a price target of $728, citing the legal win, the IPF NDA acceptance and the aggressive share‑repurchase. Goldman Sachs initiated coverage with a “Sell” rating and a target of $321, arguing that the core franchise is contracting and the valuation is stretched. Consensus from FactSet remains “Buy” with an average target of $638. The stock traded at $543.86 on October 2 2026, near its 52‑week high of $596.76, and has risen roughly 20.2 % over the past five days.

Risks and unanswered questions

Revenue contraction remains a concern; nebulized Tyvaso sales fell 18 % YoY and overall franchise revenue slipped 4 % in Q2 2026. Competitive pressure from Merck’s sotatercept and emerging biosimilars could further erode the PAH market. The FDA decision on the IPF indication is not due until late April 2027—any delay would postpone the anticipated revenue uplift. Finally, the remaining $500 million of the $2 billion buy‑back program may be exhausted by early 2027, potentially removing a key source of EPS‑boosting financial engineering.